Plasticity in binding confers selectivity in ligand induced protein degradation
暂无分享,去创建一个
James E. Bradner | Eric S. Fischer | Nathanael S. Gray | Dennis L. Buckley | J. Bradner | N. Gray | Tinghu Zhang | Mark P. Jedrychowski | J. Mancias | N. Safaee | E. Fischer | Tinghu Zhang | M. Ishoey | R. Nowak | S. DeAngelo | Zhixiang He | K. Donovan | Jian An | Charles M. Ponthier | Nozhat Safaee | Radosław P. Nowak | Stephen L. DeAngelo | Dennis Buckley | Zhixiang He | Katherine A. Donovan | Jian An | Mette Ishoey | Joseph D. Mancias | E. S. Fischer
[1] Dennis L. Buckley,et al. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. , 2017, Cell chemical biology.
[2] C. Crews,et al. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. , 2017, Cell chemical biology.
[3] C. Crews,et al. Targeted protein knockdown using small molecule degraders. , 2017, Current opinion in chemical biology.
[4] Christopher J. Ott,et al. BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. , 2017, Molecular cell.
[5] Michael B. Stadler,et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase , 2017, Nature Communications.
[6] S. Armstrong,et al. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. , 2017, Angewandte Chemie.
[7] D. Lamont,et al. Structural basis of PROTAC cooperative recognition for selective protein degradation , 2017, Nature chemical biology.
[8] J. Bradner,et al. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck , 2016, Cancer.
[9] Chin-Chun Lu,et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase , 2016, Nature.
[10] C. Crews,et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer , 2016, Proceedings of the National Academy of Sciences.
[11] G. Pelosi,et al. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. , 2016, Cancer discovery.
[12] G. Petzold,et al. Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase , 2016, Nature.
[13] M. Eck,et al. SPLINTS: small-molecule protein ligand interface stabilizers. , 2016, Current opinion in structural biology.
[14] W. I. Mohamed,et al. Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome , 2016, Nature.
[15] C. Crews,et al. Small-Molecule PROTACS: New Approaches to Protein Degradation. , 2016, Angewandte Chemie.
[16] Eunhwa Ko,et al. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. , 2016, Angewandte Chemie.
[17] Dennis L. Buckley,et al. Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. , 2015, Angewandte Chemie.
[18] I. E. Smith,et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. , 2015, Nature chemical biology.
[19] I. E. Smith,et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. , 2015, ACS chemical biology.
[20] Dennis L. Buckley,et al. Selective Target Protein Degradation via Phthalimide Conjugation , 2015 .
[21] C. Crews,et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.
[22] S. Carr,et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS , 2015, Nature.
[23] A. Ciulli,et al. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 , 2015, ACS chemical biology.
[24] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[25] H. Handa,et al. Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs , 2014, Nature Structural &Molecular Biology.
[26] Jeremy L. Jenkins,et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.
[27] Edward L. Huttlin,et al. MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes , 2014, Analytical chemistry.
[28] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[29] S. Carr,et al. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.
[30] H. Handa,et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN , 2013, British journal of haematology.
[31] Piotr Sliz,et al. Collaboration gets the most out of software , 2013, eLife.
[32] Chad J. Miller,et al. A comprehensive mathematical model for three-body binding equilibria. , 2013, Journal of the American Chemical Society.
[33] W. L. Jorgensen,et al. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. , 2012, Angewandte Chemie.
[34] A. Gingras,et al. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.
[35] P. Zwart,et al. Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.
[36] B. Zakeri,et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin , 2012, Proceedings of the National Academy of Sciences.
[37] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[38] Randy J. Read,et al. Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.
[39] Jeffrey J. Gray,et al. A generalized approach to sampling backbone conformations with RosettaDock for CAPRI rounds 13–19 , 2010, Proteins.
[40] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[41] Toshihiko Ogura,et al. Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.
[42] Vincent B. Chen,et al. Correspondence e-mail: , 2000 .
[43] Paul D Adams,et al. Electronic Reprint Biological Crystallography Electronic Ligand Builder and Optimization Workbench (elbow ): a Tool for Ligand Coordinate and Restraint Generation Biological Crystallography Electronic Ligand Builder and Optimization Workbench (elbow): a Tool for Ligand Coordinate and Restraint Gener , 2022 .
[44] D. Moras,et al. A set of baculovirus transfer vectors for screening of affinity tags and parallel expression strategies. , 2009, Analytical biochemistry.
[45] John Kuriyan,et al. The origin of protein interactions and allostery in colocalization , 2007, Nature.
[46] K. Henrick,et al. Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.
[47] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[48] Naveeda Qadir,et al. Multiparameter analysis of a screen for progesterone receptor ligands: comparing fluorescence lifetime and fluorescence polarization measurements. , 2005, Assay and drug development technologies.
[49] R. Deshaies,et al. Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[50] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[51] Ballard,et al. Overview of the CCP 4 suite and current developments , 2022 .